Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dapagliflozin + Metformin MR FDC vs. Co-administration in Healthy Volunteers
NCT02722239Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Concentration at 72 hours, Area Under the Concentration-Time Curve (AUC0-t) at 72 hours and 3 more. Started Mar 2016; status: completed.
02
Drugs
dapagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02722239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722239.